Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Forest’s Recent Launches Boosting Diversity, But Gaining Traction Slowly

This article was originally published in The Pink Sheet Daily

Executive Summary

One exception to the slow-growth outlook is the surprise success of Bystolic (nebivolol), the 16th beta blocker to enter the heavily generalized market, but a product the firm has been able to differentiate more by its tolerability than its efficacy.

You may also be interested in...



Ironwood/Forest Talk Ballpark Pricing For Linzess, Gear Up For Q4 Launch

Locally-acting linaclotide wins FDA approval for two indications – chronic idiopathic constipation and constipation-predominant irritable bowel syndrome – with no limits on length of use, a development that could reinvigorate the GI space.

Carl Icahn’s Partial Victory In Battle For Forest: One Board Seat

Primary care-focused pharma reports that preliminary voting results show former OSI executive Pierre Legault was elected to the Forest board, replacing long-time member and outgoing compensation committee Chairman Dan Goldwasser.

Biopharma Datebook: What’s On The Agenda This Week

Events on tap include release of GWU’s obesity drugs outcomes report, developed at FDA’s request, and the sure-to-be contentious Forest shareholders meeting.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS074388

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel